drugset / Trial / NCT01453127

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127 ↗

Phase 4 Enrolling by invitation 500 enrolled Mayo Clinic
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.

Timeline

Start
2011-10
Primary completion
2026-12
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject I-123 Ioflupane Diagnostic / imaging agent — Intravenous